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Abstract 
 Group B saponins, the predominant form of saponins in heat-treated soy products, have 
been shown to possess hypocholesterolemic, antimutagenic, and anticarcinogenic properties.  
Previous studies have evaluated crude mixtures of soyasaponins, but studies evaluating a single 
purified soyasaponin as an anticarcinogenic agent are limited.  The goal of this study is to 
examine the effects of purified soyasaponins I and III as well as their aglycone form, 
soyasapogenol B, as anticarcinogenic agents on the human colon adenocarcinoma cell line Caco-
2.  Experiments were conducted to determine the effects of purified soyasaponins on cell 
proliferation, Protein Kinase C (PKC) activity, and cell morphology in cultures of Caco-2 cells.  
Treatment of cells with soyasaponins I and III at concentrations of 300–900 ppm significantly 
reduced viable cell numbers after 48 and 72 hours of exposure by 10-35% (p<0.05). 
Soyasapogenol B at a concentration of 100 and 150 ppm significantly reduced viable cell 
numbers after 24 hours by 15 and 62%, respectively (p<0.05).  Cell morphology changes 
demonstrated that as concentrations and lipophilicity of soyasaponins increased, cell membranes 
became rougher and more irregular. Treatment of cells for 72 hours significantly reduced the 
amount of PKC activity by 9-40% (p<0.05).  Results indicate that purified soyasaponins I, III 
and soyasapogenol B, at physiologically relevant doses, can suppress Caco-2 colon cancer cell 
proliferation. These findings suggest that purified group B soyasaponins and their final 
metabolite soyasapogenol B may be a colon-cancer suppressive component of soy that warrants 
further examination as a potential nutraceutical or functional food. 
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Chapter I. Introduction 
 
 Colorectal Cancer (CRC) is the third most commonly diagnosed cancer and is the second 
leading cause of mortality in the U.S., causing an estimated 49,920 deaths in 2009 in addition to 
the 146,970 new cases that were also reported [1].  According to the American Cancer Society, 
the lifetime risk of being diagnosed with cancer of the colon or rectum is 5.5% for men and 5.1% 
for women in the US.  Remarkably, only 20-25% of CRC cases occur among individuals with a 
family history of CRC or a predisposing condition and the remaining 75% of cases occur in 
people without these risk factors [2].  Prevalence of CRC has been declining in the U.S. since 
1998, however, worldwide incidence and deaths from colon cancer are generally increasing, 
especially in the developed world and urban areas of developing countries [3]. North America, 
Australia/New Zealand, Western and Eastern Europe have the highest colon cancer rates.  These 
areas account for over 63% of incidence worldwide [3].  In what used to be considered low risk 
areas like Central and South America, Asia, and Africa, rates are beginning to increase as well 
[4].  Because of these large geographic differences, it is likely that a number of factors affect the 
likelihood of developing colon cancer; among them being heredity, sex, age, race, pre-existing 
conditions, lifestyle, and diet.  
 The goal of this study was to evaluate the effects of the predominant soyasaponin in heat 
treated soy products (soyasaponin I) and its two predominant metabolites (soyasaponin III and 
soyasapogenol B) on human colon cancer cells.  The hypothesis of this study is that purified 
soyasaponin I and its metabolites are more effective at suppressing colon cancer cell growth than 
crude mixtures of soyasaponins. The objectives of this study were 1) to investigate what 
soyasaponins are most effective at inhibiting colon cancer cell growth and 2) to determine at 
what concentration they are most potent.  To accomplish these objectives, cell viability and 
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protein kinase C (PKC) were measured and cell morphology changes were observed.  The effects 
of soy and other topics important to the development of colon cancer will be addressed in the 
following review. 
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Chapter II. Review of Literature 
Colon Cancer 
 Colon cancer is the product of both environmental and hereditary factors that have yet to 
be completely identified or understood.  Data from numerous epidemiological studies indicate 
diet and soy consumption as important factors contributing to the risk and development of certain 
types of cancer, particularly breast, prostate, and colon.  Investigations into the relationship 
between cancer and soy intake has led scientists to conclude that phytochemicals within soy are 
responsible for these effects, and that the mechanisms by which different phytochemicals exert 
their effects are as varied as the phytochemicals themselves.   
 
Pathogenesis of Colon Cancer 
 The development of colon cancer is a multistep process that is a consequence of a closely 
tied, but not fully understood, interaction between genetic and environmental factors [5].  A 
defining characteristic of colon cancer is the step-wise progression from normal colonic tissue to 
the malignant cell growth that is associated with chronological molecular deviations leading to 
tumor development [6]. It was discovered in the 1990s that the accumulation of activated 
oncogenes and the inactivation of tumor-suppressor genes that the colorectal epithelium 
progresses from a normal phenotype to one that is hyperproliferative and malignant in nature [5].  
 Sporadic CRC is one of the most common malignancies worldwide; because of this, there 
has been much research done in order to elucidate the underlying causes. This has revealed  
complex processes that lend to the generation of the required mutations and identification of 
various groups of target genes that govern the biological behaviors which are seen in tumor cells 
[7].    
 4 
 
 As mentioned above, colon cancer development is a multi-stage process in which altered 
cells progress to precancerous lesions such as adenomatous polyps, that if given enough time, 
will develop into carcinomas.  The gastrointestinal epithelium is a complex microenvironment 
that is composed of at least four different interconnected cell types.  In addition to other cell 
types, absorptive enterocytes, goblet cells, Paneth cells, and enteroendocrine cells are 
characterized by a tightly-regulated succession of cell proliferation, maturation, differentiation, 
and apoptosis [7]. The genetic model proposed by Fearon and Vogelstein [5] indicates that a 
hyperproliferative colonic epithelium is the first step towards colon cancer development.  
Populations that are at high risk (advanced age, genetically predisposed, presence of 
adenomatous polyps, or familial adenomatous polyposi [FAP]) have been shown to have 
increased mucosal cell proliferation throughout their colon [7]. Gene mutations and/or deletions 
accompany the promotion of a hyperproliferative normal crypt to an adenoma. It is during this 
initiation stage that the gatekeeper genes which are responsible for the control of cell 
proliferation, differentiation, migration, and apoptosis within the colonic mucosa are altered [8-
11]. The transformation to a cancerous state is often associated with the loss of several more 
genes including those that prevent cells with damaged DNA from progressing to the S-phase of 
the cell cycle, which thereby makes them responsible for the repair of DNA before allowing 
another round of cell division [12-14].  
 Increased proliferation is seen in adenomas when compared to normal epithelium, and in 
addition to this, a shift in the proliferation toward the luminal surface of the epithelium occurs in 
adenomas as well as aberrant crypt foci (ACF) [7, 15].  Indicators of the increased colorectal 
crypt cell proliferation and of the expansion of the proliferative zone toward the luminal surface 
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of the crypts have been identified. These indicators are of interest because they are biomarkers of 
future risk for the development of colon tumors [5, 16, 17].   
 ACF are induced by colon specific carcinogens in a dose dependant manner, evolve from 
one altered crypt, and exhibit preneoplastic features (dysplasia, abnormal cell proliferation 
patterns, and various gene mutations) [18]. ACF have shown to be larger than normal crypts, 
show increased branching and proliferation, and reportedly contain cells which demonstrate a 
variety of changes that indicate they are at an early stage in the process of cancer development 
[19-21].  In addition to rodent models, ACF have been described in human colonic mucosa as 
well [22-25].  Perhaps more importantly is the fact that they are predictors of tumor outcome and 
are a valuable tool for quantifying risk [15, 18, 26].  It is because of these characteristics that 
ACF are of concern to researchers interested in the early morphological changes which take 
place in the development of tumors or adenocarcinomas.  
 
Epidemiology 
 Numerous studies and reports have shown that cancer is a widespread disease, and 
according to the World Health Organization (WHO), was responsible for 7.9 million deaths in 
2007. Whereas the universality of cancer is not disputed, the distribution of certain cancer types 
and target organs is distributed unequally among different countries, those who live in urban 
areas as compared to rural areas, people of different ethnicities, race, socioeconomic status, and 
sex [27].  Such variations are inevitably due to genetic variations, environmental factors, and 
diet.   
 According to the International Agency for Research on Cancer, worldwide rates of CRC 
have variances of up to 25-fold, the highest rates being found in the developed world and the 
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lowest in India. However, even within this one country, there are differences in CRC incidence 
between populations, such as the increased rates of the Westernized Parsi and the strictly 
vegetarian Janists [28].  Supporting evidence for this trend can be seen in migrant studies, such 
as Japan to USA and Eastern Europe to North America. When studying the change in CRC rates 
among immigrants, when populations moved from low- to high-risk areas, the connection to 
environmental factors becomes quite evident; the rate of CRC increases rapidly, indicating that 
dietary as well as other environmental factors contribute a great deal to risk development [29, 
30]. Proof of this can be seen in Japanese individuals who were born in the USA now having 
higher rates than those of US whites, and the rates of colon cancer of Japanese living in Hawaii 
and Los Angeles are among the highest in the world [31]. Migrant studies have also shown 
incidence rates of migrants and their descendants reaching that of the host country, sometimes 
even within one generation [4]. These studies demonstrate how a change from a plant-based diet 
to a Westernized diet affects the etiology of colorectal malignancies and shows a clear 
relationship between diet and cancer risk, thereby making it of considerable interest to those in 
the medical field as well as nutrition researchers.  
 
Diet and Colon Cancer Relationship 
 Genetics and environmental factors can only explain so much, considering that genetic 
factors alone are only believed to explain roughly 5% of all cancers [32]. With that in mind, it is 
estimated that approximately 66-75% of CRC could be prevented by proper diet and lifestyle 
changes [4].  The role of diet in cancer prevention has been documented, but the exact dietary 
components that have greatest effect on risk have been difficult to pinpoint. The difficulty in 
showing direct relationships between dietary components and their corresponding cancer risk is 
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due in large part to inconsistent data from community- and population-based studies [32]. 
Factors contributing to these inconsistencies include the lack of an accurate measurement of 
types of dietary fat in the foods of the population under investigation as well as inconsistent 
questionnaires intended to quantify fruit and vegetable intake [17, 33].  Evidence from numerous 
cohort and case-control studies has shown that there is an inverse relationship between diets rich 
in fruits and vegetables and cancer risk. Different factors responsible for this finding include: 
fiber intake, micronutrients (carotenoids, ascorbate, and folate among others), and 
phytochemicals [17].  
Although no strong correlation between any one particular food and the increased risk of 
colon cancer can be made, there have been many epidemiological studies which conclude that 
the consumption of soy foods may contribute to lower rates of various cancers, namely colon, 
breast, and prostate cancer in countries such as China and Japan [34-36].  Japan has been heavily 
studied for their plant-based diet, specifically their consumption of soy and soy products.  There 
has been considerable interest in the soy consumption of this country because of their lower-
than-average disease rates and the belief that soy has health benefits that go beyond the nutrients 
it provides. Several epidemiological studies [37-40] have been conducted in order to determine 
soy intake and related disease risk or incidence of the study populations.  Soy is a rich source of 
phytochemicals such as isoflavones and saponins.  Phytochemicals are non-nutrient secondary 
metabolites of plants that are biologically active. Of which, some have been shown to possess 
various activities that are beneficial to health when they are consumed as part of the diet.  
Because isoflavones have been so intensely investigated for their potential health benefits and 
because saponins are a major group of phytochemicals in soy, this review and subsequent 
research project will focus on soyasaponins. 
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Soyasaponins 
 Saponins are a group of amphiphilic and structurally complex glycosides that consist of 
one or more oligosaccharide moieties linked to a triterpenoid or steroidal aglycone ring structure 
(sapogenol).  These can be found in a variety of plants such as ginseng, Quillaja, Gypsophila, 
and soybeans.  Their surface-active properties, which are a result of their hydrophilic sugars and 
lipophilic sapogenol, are the source of the name saponin, which comes from the Latin word for 
soap “sapo” [41].  It is important to note that the bioactivity of saponins vary depending on their 
source and chemical make-up [42, 43], which includes variances between ring structures as well 
as number and type of carbohydrate moieties. 
 
Chemistry of Soyasaponins  
 Soyasaponins, as their name implies, are saponins from soybean. Soyasaponins vary in 
the composition of their soyasapogenol as well as the number, type, and point(s) of attachment of 
their sugar moieties to the soyasapogenol (Figure 1).  Originally, it was thought there were up to 
five different soyasapogenols, however, as research advanced it was determined that 
soyasapogenols C, D, and E were artifacts of hydrolysis and that there are two specific 
pentacyclic triterpenoid sapogenols to which the sugar moieties attach: soyasapogenol A and 
soyasapogenol B [44-47] (Figure 2).  A number of different sugar moieties exist, including L-
arabinose and L-rhamnose which are linked α-glycosidically, and D-glucose, D-xylose, D-
galactose, and D-glucuronic acid which are β-glycosidically-linked [41].  These sugar moieties 
are attached to position 3 of the triterpenoid aglycone by an ether linkage. Because group B 
soyasaponins are the predominant form in soy and soy products, they will be the focus of this 
literature review and subsequent research. 
  
Figure 1. Soyasaponin structure and nomenclature, adapted from Kudou 
 
DDMP  Non-DDMP 
αg V 
βg I 
βa II 
γg III 
γa IV 
 
 It appears that the group B soyasaponins (
tissue as conjugates of 2,3-dihydro
hydroxyl position and are considered to be the genuine form of saponin
connecting the DDMP molecule 
of the non-DDMP group B soyasaponins (V, I, II, III, and IV), which explains their 
predominance in heat treated soy products
soyasaponin yields maltol and the corresponding 
means DDMP group B soyasaponin
γg→III, and γa→IV.  
 
 
9 
et al. [49]
 
R1 R2 
CH2OH α-L-Rhamnose 
CH2OH Β-D-Glucose 
H α-L-Rhamnose 
CH2OH H 
H H 
αg, βg, βa, γg and γa) exist in the intact plant 
-2,5- dihydroxy-6-methyl-4H-pyran-4-one (DDMP) at the 22 
 [
to the soyasaponin is easily degraded, resulting in the formation 
 [48, 49]. The degradation of the DDMP
non-DDMP-conjugated soyasaponin. This 
 αg → non-DDMP group B soyasaponin V, β
 
48].  The bond 
-conjugated 
g → I, βa→II, 
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Figure 2. Soyasapogenol A and B chemical structures 
 
Aglycone R1 R2 
Sapogenol A OH OH 
Sapogenol B H OH 
 
Bioactivity of Soyasaponins 
 Evidence from numerous studies indicates that soyasaponins have a wide variety of 
physiological effects.  Antioxidant activity of soyasaponins, namely the DDMP-conjugates has 
been evaluated in their ability to act as free radical scavengers because of their ability to donate 
an electron from its double bond moiety [50-53].  The in vivo hypocholesterolemic effects of 
soyasaponins have been evaluated as well [54, 55].  Other in vitro studies have demonstrated 
hepatoprotective [56-58], antiviral [59-61], anti-inflammatory [61], and immune-enhancing 
properties [62].  Because of their unique structure and amphiphilic nature, soyasaponins have 
been studied for a wide variety of biological effects; however, much of the interest in 
soyasaponins lies in their anti-carcinogenic properties. 
 
Anti-Carcinogenic Activity in Tissue Culture and Animals 
 There have been multiple in vitro studies [63-75] and one in vivo study [76] conducted to 
investigate the anti-mutagenic or anti-carcinogenic properties of soyasaponins.  It is from these 
studies that we have gained more of an understanding as to how soyasaponins may suppress the 
growth of cancer cells. Through in vitro studies, the effect a known compound has on a specific 
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type of cell and cell process (i.e. apoptosis, differentiation, and proliferation) can be closely 
monitored and the molecular pathway can be elucidated, additionally, the overall effect on health 
and organ systems can be observed in animal studies. 
 
 In Vitro Studies 
 There have been numerous studies which utilized different soyasaponins and 
soyasapogenols at various concentrations and have displayed anticarcinogenic properties in 
several different carcinoma cell lines [63-66, 68, 71-75, 77]. The results of these studies are 
summarized in Table 1.  From the studies listed, it is apparent that there are several factors that 
contribute to the observed effects of soyasaponins and their sapogenol on cancer cell lines.  The 
first of these factors is the testing material itself.  The majority of these studies utilized a crude 
mixture of all group-A and group-B soyasaponins or just group-B soyasaponins, whereas others 
used semi-purified individual soyasaponins.  The use of crude extracts makes it difficult to match 
a result observed in the cells to a molecular action of a specific soyasaponin.  Because of this, 
studies with purified soyasaponins are very important for identifying how purified soyasaponins 
affect bioactivity and the mechanisms involved in cell growth and viability.  The second factor is 
the dose.  Concentrations ranging from 6.25-2400 ppm have been used in various studies 
yielding different degrees and types of cell suppression. The third factor affecting results is the 
incubation time. Most studies monitor cell growth and viability at 24, 48, and 72 h, however this 
can vary from as little as 4 hours [74] to as long as 5 days [63]. Such variances are bound to yield 
different results. 
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Table 1. Summary of anticarcinogenic activities of soyasaponins and their sapogenol 
Type of 
Saponin 
Cell 
Line 
Concentration Observation Mechanism Reference 
Group-B 
soyasaponin 
mixture 
HCT-15 150-600 ppm Dose-dependent 
reduction in cell 
growth and viability 
after 48 h.  
Formation of 
cytoplasmic 
vesicles and 
deformation of 
plasma and nuclear 
membrane.  
 
[66] 
Group-B 
soyasaponin 
mixture 
HCT-15 150-600 ppm Dose-dependent 
reduction in growth 
and viability after 
48 h. Growth 
completely 
inhibited at 24 h 
with 300 and 600 
ppm. 
 
Unknown, possibly 
due to saponin-cell 
membrane 
interactions 
[67] 
Group-B 
soyasaponin 
mixture 
HT-29 150-600 ppm Dose-dependent 
reduction in cell 
growth when 
maintained for 72 h. 
Suppression of 
PKC activity and 
induction of  
differentiation  
 
[65] 
Soyasaponin I 
(89% pure) 
 
 
 
Soyasaponin III 
(86% pure) 
 
 
 
Soyasapogenol 
B (93% pure) 
HT-29 6.25, 12.5, 25, 
50 ppm 
Saponin I had no 
inhibitory effect on 
cell growth 
 
Saponin III 
suppresses growth 
at 50 ppm after 72 
h. 
 
Sapogenol B shows 
dose-dependent 
suppression from 6-
50 ppm after 72 h. 
 
The suppression of 
cell growth is 
intensified with the 
increase in 
lipophilicity. 
(Sapogenol B > 
Saponin III > 
Saponin I) 
[73] 
Group-B 
soyasaponin 
mixture 
HT-29 150-600 ppm Dose-dependent 
reduction in cell 
growth at all 
concentrations after 
72 h. 
 
Down regulation of 
COX-2 and PKC 
expression 
[64] 
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Table 1. (continued) 
Type of 
Saponin 
Cell 
Line 
Concentration Observation Mechanism Reference 
Soyasaponin I 
 
 
Soyasapogenol 
B 
Caco-2 Soyasaponin I 
470-2800 ppm 
 
Soyasapogenol 
B 
230-1375 ppm 
Soyasaponin I 
had no effect on 
cell viability 
 
Soyasapogenol 
B significantly 
reduced cell 
viability at 230 
and 1375 ppm 
after 4 h 
 
unknown [74] 
Group-B 
soyasaponin 
mixture 
HCT-15 25-500 ppm Suppress 
proliferation 
dose-
dependently and 
induced 
macroautophagy 
at 100 ppm after 
24 h 
 
Cells delayed in 
S-phase of cell 
cycle. 
[71] 
Group-B 
soyasaponin 
mixture 
 
Soyasapogenol 
B 
Caco-2 25-100 ppm Group-B 
soyasaponins 
had no effect on 
cell growth. 
 
Soyasapogenol 
B significantly 
reduced cell 
growth at 25, 50, 
and 100 ppm 
 
No mechanism 
offered. 
However, no 
negative effects 
on cell 
morphology were 
observed. 
[77] 
Group-B 
soyasaponin 
mixture 
HT-29 150-2400 ppm Decreased cell 
viability in dose-
dependent 
manner, 
suppressed PKC 
activity, and 
increased AP 
activity 
Induction of cell 
differentiation at 
lower 
concentrations 
and induction of 
type II 
autophagic death 
at higher 
concentrations 
 
[63] 
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 Proposed Mechanism of Anticarcinogenic Properties of Soyasaponins and  
 Soyasapogenols In Vitro 
  From published research, it appears as though there may be more than one mechanism of 
action for the anticarcinogenic effects of soyasaponins.  With regard to human colon cancer cell 
line studies, there have been two widely proposed mechanisms by which soyasaponins elicit their 
effects. One is the induction of cell differentiation through increases in alkaline phosphatase 
(AP) and reductions in protein kinase C (PKC) [63-65], and the other is induction of type II 
autophagic death or macroautophagy [63, 71].  PKC is a marker for cell proliferation and its 
activity increases as cells undergo the proliferation process.  AP is used as a biomarker to 
indicate differentiation in cells.  Studies which monitored the activity of AP and PKC showed 
that treatment with saponins at lower concentrations were able to induce cell differentiation.  
Type II autophagic death, or macroautophagy has been observed in two different studies [63, 71] 
through scanning electron microscopy (SEM), to observe differences in cell morphology, and 
transmission electron microscopy (TEM), to observe differences in intracellular morphology.    
In addition to the changes in cellular morphology visible by SEM, under TEM observation, 
vacuoles appeared in the cells that had been treated with higher concentrations of soyasaponins.  
This observation was also seen in the study by Ellington et al. [71] along with decreased cellular 
density, the absence of mitochondria, and prominent vacuoles containing degraded cellular 
material.  All of these observations indicate that treatment of cells with group-B soyasaponins 
does not directly induce apoptosis, but instead induces morphological changes supportive of type 
II autophagic cell death. 
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 In Vivo Studies 
 Studies conducted which utilized soy components known to contain both soyasaponins 
and isoflavones have decreased chemically induced colon carcinogenesis in mice and [78, 79].  
However, there have been conflicting results when trying to identify specifically which 
compounds reduce carcinogenesis in animal models.  Soy protein isolate was shown to be 
protective against azoxymethane (AOM) induced tumors in rats [79]. Isoflavones and 
soyasaponins were both present in the soy protein, so there can be no definite answer as to which 
compound was effective in preventing the tumors.  Thiagarajan et al. [78] demonstrated that soy 
flour and soy flakes, products known to include soyasaponins and isoflavones, as well as the 
isoflavone genistein significantly reduced the incidence and multiplicity of ACF in AOM treated 
rats.  They also demonstrated that ethanol washed soy protein concentrate, a product devoid of 
soyasaponins, did not reduce the incidence or multiplicity of ACF in these rats.  Conflicting 
evidence from a study conducted by Rao et al. [80] demonstrated that a diet supplemented with 
250 ppm of genistein enhanced carcinogenesis in AOM treated male rats.  Because of conflicting 
results regarding isoflavones, genestin in particular, and because ethanol washed soy does not 
reduce carcinogenesis in animal models, it appears as though soyasaponins may be responsible 
for the effects seen in the studies which utilized soy protein or soy flour.   
 The in vivo study mentioned earlier by Koratkar and Rao [76] evaluated the 
anticarcinogenic effect of a soyasaponin extract containing 8-10 different soyasaponins on an  
AOM treated CF-1 mouse model.  AOM is a colon cancer specific carcinogen intended to initiate 
cancer in rodents which rarely develop sporadic cancer in nature.  One week postinitiation, the 
mice were placed on a basal AIN-76 diet containing no saponins or one containing 3% 
soyasaponin by weight. At the end of the 14 week feeding period, the mice were sacrificed and 
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colons were evaluated for ACF using the method from Bird et al. [18].  In this study, the 
consumption of soyasaponins significantly reduced the incidence of ACF as well as the number 
of aberrant crypts per focus.  The authors suggest that the soyasaponins had undergone microbial 
hydrolysis of their sugar moieties in the cecum and large intestine, and that because the 
soyasaponins are not absorbed from the gastrointestinal tract it is likely that they can interact 
with free or membrane-bound sterols as well as bile acids.  This hypothesis agrees with research 
evaluating the interaction of soyasaponins with bile acids [81-84] and research evaluating the 
hypocholesterolemic effect of soyasaponins [54, 55].   
 
 Proposed Mechanism of Soyasaponins in the Prevention of Colon Cancer In Vivo 
 Within animal models, the ability of soyasaponins and their soyasapogenol to bind with 
bile acids is widely accepted as the mechanism by which they elicit cholesterol-lowering and 
anti-colon cancer effects.  Bile acids are the major end products of cholesterol metabolism and 
are formed in the liver. From the liver, they are concentrated and stored in the gallbladder where 
they can be secreted into the small intestine to act as cholesterol solubilizing agents and aid in 
lipid digestion and absorption.  Under normal conditions, approximately 95% of bile acids 
passing through the ileum are reabsorbed through the portal vein and return to the liver to be 
secreted again as part of the enterohepatic circulation.   
 Primary bile acids which have been transformed to secondary bile acids have been 
implicated in the carcinogenic process.  These amphiphilic molecules are formed in the large 
intestine by the enzymatic deconjugation and dehydroxylation of primary bile acids by anaerobic 
colonic bacteria [85].  Secondary bile acids trigger a cascade of events within the colon, each 
leading to another event potentially resulting in cancer development.  
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The secondary bile acids, like lithocholic acid, can be co-mutagenic due to their ability to 
cause DNA strand breaks [86, 87].  Additionally, they are cytotoxic and are disruptive to the 
colonic mucosal cell membrane integrity [88]. The resulting cell loss stimulates a response by 
the body to increase cellular proliferation in an attempt to compensate. There is also evidence of 
a direct stimulatory effect on proliferation mediated by protein kinase C (PKC) activation in the 
colonic cells [89]. In many cell systems the activation of PKC can lead to the induction of 
proteins that form transcription factor AP-1 [89]. Bile acids and lipid components in the aqueous 
fraction of the stool can activate AP-1, whose activation has been associated with promotion of 
neoplastic transformation [90].   
Colon cancer is rarely the result of one single event; typically, it is the final outcome of 
the interplay between a number of different genetic and environmental variables. One example of 
this would be the inhibition of apoptosis by deregulation of a number of oncogenes, which could 
result in colonal expansion. Incidentally, one of the secondary bile acids, deoxycholic acid 
(DCA) was an effective inducer of apoptosis [88, 91-93]. The enhanced apoptosis by bile acids 
might be the result of their DNA-damaging properties or their damaging effects on the colonic 
mucosa. 
 The anti colon cancer properties of soyasaponins in vivo are a result of their ability to 
bind with primary bile acids and prevent the formation of secondary bile acids.  As mentioned 
before, approximately 95% of bile acids and salts that are secreted into the duodenum are 
reabsorbed. This allows 2-5% of primary bile acids to escape to the colon and can amount to 
approximately 20% of the bile acid pool over the course of 6-12 enterohepatic circulations that 
occur daily.  The ability of soyasaponins to bind bile acids within the small intestine and their 
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soyasapogenol binding to bile acids in the colon could result in a reduction of primary bile acids 
that are metabolized by the colonic microflora into secondary bile acids.   
 From the previously mentioned information on bile acid interactions within the colon, it 
is clear that more insight into the interactions between bile acids, secondary bile acids, and 
soyasaponins could be valuable in understanding the chemopreventive properties of 
soyasaponins and their metabolites, which in turn could possibly lead to the development of 
tumor prevention strategies.  These effects seem to be stemming from actions within the lumen 
of the colon and on the mucosal cell membranes of the colon, it would be pertinent to address the 
bioavailability, effect of colonic microflora and metabolism of soyasaponins, and possible 
toxicity issues that may arise from a soyasaponin supplemented experimental diet. 
 
Bioavailability and Metabolism of Soyasaponins 
 In earlier animal studies, combinations of DDMP and non-DDMP soyasaponins were fed 
to mice, rats, and chicks [94, 95]. In these studies, saponins were found in the stomachs and 
small intestines, while only the aglycone sapogenols and a very small amount of saponins were 
found in the cecum and feces. This suggests that the sapogenols are the primary metabolites.  
 In a more recent study [75], soyasaponin I was incubated anaerobically with human fecal 
microflora to investigate how soyasaponins were metabolized and also to identify the 
metabolites. Over a 48 hr period, it was observed that as soyasaponin I decreased, soyasaponin 
III increased, and at the end of the 48 hr period the remaining product was soyasapogenol B. 
This follows a convincing pattern considering soyasaponin I has three sugars, soyasaponin III 
has two sugars, and soyasapogenol B contains no sugars.  
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 A human feeding study conducted by Hu et al. [74] featured an extract containing a 
mixture of approximately 435 µmol group B soyasaponins which was fed to a group of eight 
women. Urine and fecal samples were collected and analyzed revealing no soyasaponins in the 
urine or feces, but sapogenol B was found in the fecal material collected from the subjects. From 
this study we are able to gain some understanding of the fate of ingested soyasaponins in 
humans, but more detailed information from in vivo conditions is needed. 
 As part of the previous study by Hu et al., mucosal uptake and transepithelial kinetics of 
soyasaponin I and soyasapogenol B were measured using the Caco-2 cell monolayer model.  The 
results of this study show that the mucosal transfer rates and apical to basolateral absorptions of 
soyasaponin I and soyasapogenol B were low.  Soyasaponin I showed a saturable and 
concentration-independent transport and cell-uptake rate, however, soyasapogenol B was taken 
up by the Caco-2 cells in a concentration-dependent manner.  Results of this study confirm the 
hypothesis of other studies that soyasaponins and their sapogenol have low absorbability in 
human intestinal cells, are metabolized to the aglycone form by gut microflora, and are excreted 
in the feces. 
 
Toxicity  
An animal toxicity study was performed by MacDonald et al., [77] in which young 
C57blackJ mice were fed increasing amounts of purified soyasaponins (0-3% by weight) for 4 
weeks.  The treatment had no negative effects on body weight gain, organ weight, or colon-
mucosal parameters.  The before mentioned study by Hu et al., [74] demonstrated that 
soyasaponins have poor absorption in the human body and are metabolized by the microflora 
within the gastrointestinal tract and are excreted in the feces.  Also, the safety of soyasaponins in 
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feedstuffs [96] and commonly used food items [97] has been established.  In addition to their 
safety, the quantification of soyasaponins in commonly used soy foods has been determined as 
well [98]. 
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Chapter III. Materials and Methods 
Soyasaponin I, III, and Soyasapogenol B Preparation 
 Soyasaponins I and III were isolated from soybeans that were grown as part of a study 
evaluating elicitor spray on soybeans and soyasaponin content at the University of Arkansas, as 
well as from a mixture of soyasaponins that was generously provided by Organic Technologies 
(Coshocton, OH).  Total group B soyasaponins were extracted from whole soybeans by first 
coarsely grinding with a spice grinder to break the seeds, and then finely ground using a cyclone 
mill (UDY Cyclone Lab Sample Mill Model 3010-030), after which the ground soybean meal 
was passed through a 60 mesh sieve.  The ground soybean meal was defatted using n-hexane in a 
Soxhlet apparatus.  The remaining defatted soybean meal was then extracted for 2.5 hours with 
70% ethanol in an Erlenmeyer flask on an orbital shaker at room temperature.  Afterwards, the 
extraction mixture was filtered through Whatman no. 1 filter paper and collected in a round 
bottom flask.  The soybean extract was rotary evaporated at 30°C. The remaining syrup-like 
residue was resuspended in water and freeze dried.  HPLC analysis of the resulting soybean 
extract showed 10 different soyasaponins and there were no interfering isoflavones present.  The 
soybean extract was fractionated via semi-prep HPLC as well as used as the starting material for 
alkaline hydrolysis. 
 Alkaline hydrolysis was used to convert DDMP-conjugated soyasaponins into non-
DDMP soyasaponins, which was necessary for acquiring soyasaponins I and III.  A modified 
method from Zhang et al. [99] was used for the alkaline hydrolysis, beginning with 100 mg of 
crude soyasaponin extract which was suspended in anhydrous methanol containing 5% NaOH 
(v/v).  The mixture was placed in a closed reaction vessel and placed in an 80°C water bath for 
30 minutes.  After cooling, the reaction mixture was neutralized with concentrated HCl, diluted 
 22 
 
with D.I. water to 50% methanol, and loaded on a preconditioned 10g C18 Sep-Pak column 
(Grace Davison, Deerfield, IL).  The column was washed with water (100 ml) and the 
hydrolyzed mixture was then eluted with 80% methanol (50ml) and collected to be dried.  
Finally, the column was rinsed with 100% methanol to remove any remaining non-polar 
compounds; the column could then be reused.  After rotary evaporation and subsequent freeze 
drying, the hydrolysis powder was subjected to HPLC analysis for confirmation of degree of 
hydrolysis and soyasaponins present.  Soyasaponins V, I, II, and III were obtained in this manner 
via fractionation by semi-prep HPLC (Shimadzu Prominence CBM-20 Communications Bus 
Module, SPD-M20A Diode Array Detector, LC-20AB Liquis Chromatograph Pump) utilizing a 
reverse phase C18 YMC-Pack ODS-AM 250 x 10mm I.D. column. 
 The harsh conditions provided by 3N HCl and a boiling water bath are sufficient to 
cleave all carbohydrate moieties from the triterpene unit, but leave the aglycone 5-ring structure 
intact, and thus soyasapogenol B will be produced by acid hydrolysis using a modified method 
from Hu et al. [74].  250 mg of group B soyasaponins provided by Organic Technologies 
(Coshocton, OH) were refluxed with 100 ml of 3N HCl in a boiling water bath for 45 minutes.  
The reaction mixture was quickly cooled and neutralized with 10N NaOH.  The neutralization 
process resulted in salt forming due to the interaction of HCL + NaOH → NaCl + H2O.  The 
reaction mixture was desalted and the remaining sugars were removed by loading the mixture on 
a preconditioned 10g C18 Sep-Pak column (Grace Davison, Deerfield, IL) and washed with 
increasing percentages of methanol.  The soyasapogenol B fraction is eluted using 200ml of 
100% methanol.  The fraction was rotary evaporated at 30°C, suspended in water, and then 
transferred to another flask to be freeze dried.  The resulting powder is then ready to be further 
purified via semi-prep HPLC (Shimadzu Prominence CBM-20 Communications Bus Module, 
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SPD-M20A Diode Array Detector, LC-20AB Liquis Chromatograph Pump) utilizing a reverse 
phase C18 YMC-Pack ODS-AM 250 x 10mm I.D. column. 
 
Cell Culture  
 Caco-2 human colon cancer cells were purchased from the American Type Culture 
Collection (ATCC, Rockville, MD) at passage number 18 and cultured in Dulbecco's modified 
eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% Non-essential 
amino acids, 2% antibiotic-antimicotic, and incubated at 37°C in a humidified 5% CO2 
atmosphere.  All media components and reagents were obtained from Gibco® through Life 
Technologies (Carlsbad, CA). 
 
Cell Viability Assay  
 Cells at passage numbers 30-31 were used for the following proliferation assays. Cellular 
proliferation and viability were measured using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega Corp. Madison, WI).  This assay is a colorimetric method for 
determining the number of viable cells in proliferation or cytotoxicity assays.  The CellTiter 
reagent contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron 
coupling reagent (phenazine ethosulfate; PES).  
 The MTS tetrazolium compound is bio-reduced by living cells into a colored formazan 
product which is soluble in culture medium.  The assays are performed by adding a small amount 
of the CellTiter reagent directly to culture wells in a 96 well plate, incubating for 1-4 hours 
(depending on the metabolic rate of your cells), and then recording the absorbance at 490nm with 
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a plate reader (Synergy HT Multi-Mode Microplate Reader, BioTek Instruments, Inc., Winooski, 
VT).  The quantity of formazan product measured by the absorbance at 490nm is directly 
proportional to the number of living cells in culture, as seen in Figure 3. 
 To perform this assay, (2 x 103) Caco-2 cells in 100µl of DMEM containing 10% fetal 
bovine serum were seeded in the wells of a 96 well plate and incubated at 37°C and 5% CO2.  
After stable attachment (48 hrs) media was removed and replaced with test media containing 
soyasaponins I, III, and sapogenol B at concentrations of 0, 300, 600, and 900 ppm.   
 Viability measurements were made at 4 different time points: 0, 24, 48, and 72 hrs.  this 
was accomplished by adding 20µl of CellTiter reagent directly to the wells containing cells as 
well as wells containing only the test media (to be used as a sample control) and incubating for 4 
hours before measuring the absorbance at 490nm.   After all absorbance readings had been made, 
corrections were made for the background absorbance of the control media as well as the sample 
control media which contained soyasaponins.  Absorbances were then converted into cell 
numbers using an equation from the Caco-2 cell standard curve completed earlier in which a 
serial dilution of cells was prepared in triplicate in a 96 well plate which ranged from 350 cells 
per ml to 70,000 cells per ml.  After the dilution was complete, CellTiter reagent was added and 
absorbances were recorded after 4 hours.  After absorbances were converted into cell numbers, 
cell growth curves were then plotted. 
 
Light Microscopy of Cells 
 Cell morphology was observed using a Nikon Eclipse E400 light microscope with Nikon 
Camera Head DS-Fi1.  Cells from passage number 41 were used to visualize morphology 
changes.  After 72 hours of treatment with soyasaponin I, III, or soyasapogenol B, cells were 
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harvested and an aliquot was taken from the cell suspension.  A portion of the aliquot was then 
stained with trypan blue dye to determine viable from non-viable cells and also to provide 
contrast.  10µl of the aliquot was then pipetted onto a slide and covered with a cover-slip.  The 
prepared slides were viewed under low power magnification until an acceptable cell was 
identified.  The cell of interest was then viewed under higher power (400x).  Using the Nikon 
camera software, contrast and color was adjusted to provide the best possible image, after which, 
a still shot was taken and saved for later viewing. 
 
PKC Assay 
 Cells at passage numbers 39-40 were used for PKC enzyme activity assays.  PKC activity 
was determined with the PepTag® Non-Radioactive PKC assay kit (Promega Corp. Madison, 
WI).  The PepTag® Assay utilizes a brightly colored fluorescent peptide that it highly specific for 
PKC, which phosphorylates the PKC peptide, thus changing its net charge from +1 to -1.  The 
change in net charge of the substrate allows the phosphorylated and non-phosphorylated versions 
of the substrate to be rapidly separated on an agarose gel.  The color of the PepTag® Peptide 
substrate is imparted by the addition of a dye molecule, which allows for easy visualization of 
the bands during the electrophoresis process.  After electrophoresis, the bands can be excised, re-
solubilized, and quantified by reading their absorption on a plate reader at 570nm. 
 For this assay, 5 x 106 Caco-2 cells were seeded in a 75cm2 flask.  After stable 
attachment, media was removed and replaced with test media containing 300, 600, and 900ppm 
of soyasaponins I and III and 50, 100, and 150ppm of sapogenol B, as well as media containing 
no soyasaponins or soyasapogenol B.  All media except that of the negative control contained 
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12-O-tetradecanoyl phorbol 13 acetate (TPA) (100ng/ml), a known PKC stimulator.  The cells 
were then incubated for 72 hrs at 37°C and 5% CO2.   
 After the incubation time was over, all media was collected, cells were rinsed with 
phosphate-buffered saline (PBS), the cells were trypsinized, removed from the flask, and the 
flask was rinsed again with PBS to collect all remaining cells.  To pelletize the cells, the mixture 
was centrifuged and all supernatant was completely removed.  The cells were then suspended in 
0.5ml of cold PKC extraction buffer (Table 2) and then homogenized by using multiple freeze 
thaw cycles and a probe sonicator (XL-2000 Q Sonica, LLC, Newton, CT).  The cell lysate was 
then centrifuged for 5 minutes at 4°C, 14,000 x g in a microcentrifuge.  The supernatant was 
passed over a 1ml column of Whatman diethylaminoethyl cellulose that had already been 
preconditioned with PKC extraction buffer.  The column was washed with 5ml of PKC 
extraction buffer.  The PKC-containing fraction was eluted using 5 ml of PKC extraction buffer 
containing 200mM NaCl.   
 For each sample, the PepTag® Reaction 5X buffer, PepTag® C1 peptide, PKC Activator 
5X solution, and DI water was added to a 0.5ml microcentrifuge tube and kept on ice until the 
sample was ready to be added.  At time zero, the tubes were removed from the ice and incubated 
in a 30°C water bath for 2 minutes.  Then, the sample was added and incubated for another 30 
minutes at 30°C.  The reaction was stopped by placing the tubes in a boiling water bath for 10 
minutes.  The samples were stored at 4°C in the dark until they were ready to be loaded on the 
gel. 
 A 0.8% agarose gel was prepared using 50mM Tris-HCl pH 8.0.  The solution was heated 
until the agarose was completely dissolved and was allowed to cool to approximately 60°C 
before pouring into the gel tray.  Only one comb was used and it was placed in the middle of the 
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gel. The gel was allowed to solidify for 30 minutes.  The horizontal gel apparatus was assembled 
according to the manufacturer’s specifications. 
 After the gel had solidified, it was placed in the electrophoresis chamber and the comb 
was gently removed.  50mM Tris-HCl (pH 8.0) was poured over the gel until the gel was 
covered completely.  Before loading the samples, 1µl of 80% glycerol was added to each sample 
to ensure it stayed in the well.  Immediately after the last sample was loaded, the gel was run at 
100V for 15-18 minutes.  Once the electrophoresis was complete, the gel was removed from the 
chamber and photographed under UV light to provide for greater sensitivity.   
 Using a scalpel, the negatively charged bands were quickly excised to avoid diffusion.  
The excised band was then placed into a 1.5ml microcentrifuge tube and heated at 95°C until the 
gel slice was melted.  125µl of the hot agarose was pipetted into a tube containing 75µl of Gel 
Solubilization Solution and 50µl of glacial acetic acid.  The mixture was quickly vortexed and 
transferred to a well in a 96-well plate.  After all the samples had been transferred to the 96-well 
plate, the absorbance was read at 570nm.  The plate reader was blanked by using liquefied 
agarose without PapTag® Peptide.  The activity of PKC in the samples was then calculated using 
the absorbances seen in the PKC positive control dilution assays. 
 
Statistical Analysis 
 Data will be analyzed using Statistical Analysis System (Version 9.2; SAS Institute Inc., 
Cary, NC).  Results will be analyzed using one-way analysis of variance using an alpha level of 
0.05 followed by Fisher’s least significant difference (LSD) test. Data is presented as means ± 
standard error of the mean (SEM). 
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Chapter IV. Results 
Soyasaponins I, III, and Soyasapogenol B inhibit proliferation of Caco-2 Cells. 
 Treatment of cultures of Caco-2 cells with soyasaponins I, III and soyasapogenol B 
decreased cell proliferation in a time and concentration-dependent manner (Table 3, Figure 4, & 
5).  As early as 24 h after initiation of soyasapogenol B treatment, viable cell numbers were 
significantly reduced by 14.7-62.4%, compared with the control, at concentrations of 100-150 
ppm respectively (p<0.05) (Table 3). After 48 h of treatment, Soyasaponins I and III at all 
concentrations reduced viable cell numbers by 9.6-34.6% (p<0.05) (Table 3). Similarly, after 72 
h of soyasaponins I, III, and soyasapogenol B treatment viable cell numbers were significantly 
reduced by 46.3-94.3%, compared with the control (p<0.05) (Table 3). 
 
Light Microscopy 
 Figure 6 shows the light microscope observations of Caco-2 cells treated with 0, 300, 
600, and 900 ppm of soyasaponins I and III (Figure 6. (b) & (c)) as well as 50, 100, and 150 
ppm of soyasapogenol B (Figure 6. (d)). When the dose of soyasaponins increased, the surface 
of Caco-2 cells became rougher, and the cell shape changed from round to irregular. As the dose 
of soyasaponin I and III reached 900 ppm, breaks were seen on the surface of Caco-2 cells. At 
the highest concentrations of soyasapogenol B, complete deformation of Caco-2 cells was 
observed (Figure 6 (d)). 
 
PKC Assay 
 Expression of the proliferation enzyme PKC was decreased in cells treated with 
soyasaponins I, III, and soyasapogenol B (Table 4).  Soyasaponin I reduced PKC expression in a 
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dose-dependent manner, ranging from 9.0-27.3% reduction in PKC activity compared to the 
control (p<0.05).  Soyasaponin III also reduced PKC activity in a dose-dependent manner.  
Reductions of 18.2-40.0% were seen in the soyasaponin III group (p<0.05) . The soyasapogenol 
B group showed reductions in PKC ranging between 56.4-70.9%. The 100 and 150 ppm groups 
showed significantly greater reductions than the 50 ppm group (p<0.05), but 150 ppm was not 
significantly greater than the 100 ppm group. 
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Chapter V. Discussion 
 Numerous epidemiological and experimental studies have suggested that soy contains 
several bioactive phytochemicals.  However, the possible mechanisms of their effects are not 
fully understood.  Confusion from different animal models, cell lines, and test materials have 
further complicated the task of identifying what soy phytochemicals are responsible for the 
health effects linked with soy consumption.   
 In the present study, the effects of the predominant soyasaponin in heat treated soy 
products (soyasaponin I) as well as its two primary metabolites (soyasaponin III and 
soyasapogenol B) were tested to evaluate their effect on cell growth, cell morphology changes, 
and proliferation-related enzyme activity of Caco-2 human colon cancer cells.  Soyasaponins I, 
III, and soyasapogenol B effectively inhibited the growth rate and survival of human colon 
cancer cells, altered cell morphology, and inhibited the TPA-stimulated PKC activity in a dose-
dependent manner. 
  Soyasaponins I, III and soyasapogenol B decreased cell proliferation in human colon 
cancer cells in a time and concentration-dependent manner (Table 3).  Cell proliferation and 
viability data from this study compare favorably with previous research [65-68, 72]. However, 
these studies utilized different cell lines HT-29 and HCT-15, different soyasaponin mixtures, and 
concentrations.  When comparing the data of these studies, it is important to look at the growth 
curves of both the control cells and the treatment cells.  Control cells display an exponential 
growth curve, but depending on the cell line, the slope of that line may vary in steepness.  The 
doubling time of HT-29 cells and HCT-15 cells vary, but is approximately 24 hrs. Caco-2 cells 
on the other hand are metabolically slower and double approximately every 62 hours.  
Depending on the study, cell proliferation and viability studies used different methods.  Some 
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studies plated a specific density of cells in 35mm cell culture plates and determined cell count 
and viability using a hemocytometer and trypan blue [64-67], while others used 96 well plates 
and a chemical reagent which would be bio-reduced to form a colored product which could be 
quantified using a plate reader [63,73].  Either method produces similar growth curve patterns.  
So, even while all the control growth curves are not identical, they follow an exponential pattern.  
Treatment-cell growth curves vary from study to study, but they too follow a similar pattern, in 
that they always respond in a dose-dependent manner and are generally similar to the negative 
control curve, but differ in steepness.  An example of this can be seen in figure 7 [66].  In the 
present study, the cell growth curves of the treatment groups, up to 48 hours, resemble those of 
the before mentioned research [66].  Where this study varies from previous research is that 
depending on the treatment group, the growth curves do not continue upwards after 48 hours.  
Depending on treatment group, the cells plateau after 24 hours or begin to die off after 48 hours 
eventually returning to near 0 hour cell numbers after 72 hours.  The soyasapogenol B data tells a 
somewhat different story because of its increased bioactivity. Soyasapogenol B at 50 and 100 
ppm begin to follow the growth curves of previous research up to 24 hours, but after which cell 
proliferation stops and cell viability drops off dramatically leading up to the 48 and 72 hour time 
points. 
 Comparison with other studies utilizing mixtures of soyasaponins shows that the purified 
soyasaponins used in this study were more effective in reducing cell growth at lower 
concentrations.  Tsai et al. [63] reduced cell growth by 27% at 72 hours when treated with 600 
ppm of soyasaponins compared with control cells.  However, the 300 ppm soyasaponin group 
was not significantly different from the control cells.  In the current study, soyasaponins I and III 
at 300 and 600 ppm reduced cell growth by 46-55% at 72 hours (Table 3).  Three other studies 
 32 
 
[64, 66, 67] which utilized a mixture of soyasaponins demonstrated that cell growth could be 
significantly reduced by 150, 300, and 600 ppm of soyasaponins after 48 and 72 hours, but the 
percent reduction in cell growth compared to the control cells was not listed.  Even though the 
percent reduction in cell growth was not listed in these studies, it is clear when looking at the cell 
growth curves that these soyasaponin mixtures did not have the same affect that the purified 
soyasaponins in this study did.  When reaching the 48 and 72 hour time points in the previously 
listed studies, cell growth curves were still progressing steadily upwards, but in the current study, 
cell growth curves were already plateauing (48 hours) or decreasing (72 hours) (Figure 4. a & 
b). 
 In the only other study that utilized individual soyasaponins [73], soyasaponin I, III and 
soyasapogenol B were utilized at 6, 12, 25, and 50 ppm.  The study also utilized a group B 
soyasaponin mixture at those same concentrations. After 72 hours of treatment, the group B 
mixture and soyasaponin I groups had no effect on cell growth.  Soyasaponin III at its highest 
concentration reduced cell growth by approximately 25%, it’s difficult to make a comparison to 
this study, but soyasaponin III at 300 ppm reduced cell growth by 49% (Table 3).  This is a 
higher percentage, but also a higher concentration.  Soyasapogenol B at 50 ppm reduced cell 
growth by approximately 90-95% in the study mentioned above.  The current study reduced cell 
growth by 87% (Table 3), which is similar in comparison to the 90-95% reduction seen in the 
other study.  Gurfinkel et al. [73] demonstrated that the soyasaponin mixture and soyasaponin I 
did not have an effect, but soyasaponin III (with fewer sugars) and soyasapogenol B (no sugars) 
decreased cell growth. Evidence from Gurfinkel et al. [73] and the current study indicate that 
differences in soyasaponin lipophilicity have a significant effect on bioactivity and resulting 
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cancer cell growth. All this lends to the hypothesis that with greater lipophilicity there is also 
greater bioactivity. 
 By viewing under a microscope, it became evident that when treated with increasing 
concentrations of soyasaponins and soyasapogenol B, cell membranes became more rough and 
irregular.  At the highest concentrations of soyasaponin and soyasapogenol B complete 
deformation of Caco-2 cells was observed (Figure 6).  In the study by Tsai et al, [63] as 
concentrations of soyasaponins increased, the surface of the HT-29 cells became more rough and 
irregular leading up to 600 ppm. At 1200 ppm, breaks were seen on the surface of the cells, and 
at 2400 ppm, complete deformation of the HT-29 cells was observed. The changes in cell 
morphology are suggestive that soyasaponins may be binding to or inserting into the cell 
membrane.  This is particularly relevant because the membranes of some cancer cells contain 
more cholesterol than normal cell membranes. Because of this, it is also likely that soyasaponins 
bind more to cancer cells, and thus in the intestine, soyasaponins can bind to the mucosal cell 
membrane, change its physiology, and as a result reduce cancerous cell growth.  A relationship 
between cell morphology and increased lipophilicity of soyasaponins and soyasapogenol B was 
observed in this study.  Morphological changes observed through microscopy of cells indicate 
that as lipophilicity increases, cell morphology and cell membrane integrity become more 
compromised.  Cell membranes become rough and irregular with treatment of soyasaponins I 
and III. With treatment of soyasapogenol B, cell membranes were irregular and eventually 
deformed to the point where the membranes are no longer intact and the cell was completely 
deformed. 
 PKC is one of the markers for cell proliferation and its activity increases as the cells 
undergo the proliferation process.  As shown in this study, the addition of soyasaponins I, III, 
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and soyasapogenol B to the cell culture media effectively reduced the expression of PKC in 
colon cancer cells.  Previous research [64-66] has shown similar results when using crude 
mixtures of group B soyasaponins and HT-29 colon cancer cells.  Kim et al., [65] demonstrated 
that 600 ppm soyasaponins significantly reduced PKC expression after 72 hours.  Treatment with 
150 and 300 ppm did not significantly reduce PKC expression.  In the study by Oh et al., [66] 
PKC expression was significantly reduced by 300 and 600 ppm soyasaponin treatment.  
However, there was no dose dependent effect.  The reduction in PKC activity in the 600 ppm 
group was not significantly greater than the 300 ppm group, 21.4 and 20% respectively. 
 In this study, there was a dose dependent effect seen in the soyasaponin I group.  For the 
300, 600, and 900 ppm groups, PKC activity was reduced by 9.1, 16.4, and 27.3% respectively 
(Table 4).  Soyasaponin III followed a similar pattern, and reductions for this group are as 
follows: 18.2, 32.7, and 40.0%. Depending on the soyasaponin, the percent reductions in PKC 
activity of this study are close to those of the previously mentioned studies [63-65] which used 
soyasaponin mixtures.  Soyasaponin I reduction was less than the reported values in these studies 
when used at the same concentrations, but soyasaponin III had a greater reduction at the 600 ppm 
concentration compared to mixtures of soyasaponins at that same concentration. 
 Initially, it appeared that the soyasapogenol B group had reduced the PKC activity of the 
cells by 56.4, 65.5, and 70.9% (Table 4).  However, because of its increased bioactivity, after 72 
hours cell viability was extremely low, therefore, the measured reduction in PKC activity may 
not have been due to reduced expression of the protein by the cells, but rather because the cells 
were no longer alive to produce the protein.  
 Previous report has indicated that soyasaponins possess surface-active properties [67].  
Transmission electron microscopy imaging indicates that soyasaponins induced the formation of 
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vacuoles and deformations in plasma and nuclear membranes of cells [72].  By binding to or 
inserting themselves into the cell membrane, they are able to disrupt normal cell function, which 
appears to be the case with PKC.  Previous studies have suggested that the disruption by the 
soyasaponins somewhat modulates the translocation of PKC from the cytosol to the cell 
membrane [65, 66], thus reducing its expression.  As mentioned earlier, soyasaponin-cell 
membrane interactions appear to be the key mechanism by which soyasaponins elicit their 
effects.  Proliferation and viability data, microscopy results, and PKC activity from this study all 
indicate that the bioactivity of soyasaponins and soyasapogenol B are directly related to their 
molecular structure and more importantly their lipophilicity.  The differences in bioactivity are 
likely due to the fact that with increases in lipophilicity, there is more soyasaponin/ 
soyasapogenol B interaction with the cancer cell membranes, which are rich in phospholipids 
and cholesterol.  
 36 
 
Chapter VI.  Conclusion 
 The predominant soyasaponin in heat treated soy products, soyasaponin I, is metabolized 
first into soyasaponin III and finally into soyasapogenol B by colonic microflora.  In summary, 
cell proliferation and PKC activity were reduced in a dose dependent manner when treated with 
these phytochemicals. Data from proliferation and PKC assays as well as morphological analysis 
indicates that the suppression of cell growth and disruption of cell membrane integrity is 
intensified with increases in lipophilicity of the soyasaponins and soyasapogenol B, meaning that 
soyasapogenol B is greater than soyasaponin III which is greater than soyasaponin I.  The results 
of this study indicate that the predominant soyasaponin in heat treated soy products and its two 
metabolites, at physiologically relevant doses, can suppress colon cancer growth.  These findings 
suggest that purified soyasaponins and soyasapogenol B may be a colon cancer suppressive 
component of soy which warrants further examination as a potential nutraceutical or functional 
food. 
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Appendix 
 
Figure 3. CellTiter 96® AQueous One Solution Caco-2 Cell Standard Curve 
 
 
Table 2.  PKC Extraction Buffer  
Ingredients Final Concentration 
Tris-HCL (pH 7.4) 25mM 
EDTA 0.5mM  
EGTA 0.5mM  
Triton® X-100 0.05% 
β-mercaptoethanol 10mM 
Leupeptin 1µg/ml 
Aprotinin 1µg/ml 
0.5ml Stock solution (100mM PMSF in 100% EtOH) per 
100ml of PKC extraction buffer added just before use. 
 
 
 
y = 29676.18x
R² = 0.99
0
10000
20000
30000
40000
50000
60000
70000
80000
0 0.5 1 1.5 2 2.5
C
el
l N
u
m
be
r
Absorbance (490 nm)
 38 
 
Figure 4. (a) Soyasaponin I effects on CaCo-2 cell proliferation 
 
Different concentrations of Soyasaponin I at each incubation time were compared against the 
negative control using Dunnett’s test.  Points marked with (*) represent significant differences at 
the P<0.05 level. 
 
(b) Soyasaponin III effects on Caco-2 cell proliferation 
 
 
Different concentrations of Soyasaponin III at each incubation time were compared against the 
negative control using Dunnett’s test.  Points marked with (*) represent significant differences (p 
< 0.05) 
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Figure 5. (a) Soyasapogenol B effects on Caco-2 cell proliferation 
 
 
 
 
(b) Soyasapogenol B effects on Caco-2 cell proliferation 
 
Different concentrations of Soyasapogenol B at each incubation time were compared against the 
Negative Control using Dunnett’s test.  Points marked with (*) represent significant differences 
(p < 0.05) 
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Table 3. 
Soyasaponin I, III, and soyasapogenol B Percent Reduction in Cell Viability 
 
  24 Hours  48 Hours  72 hours 
Treatment Conc. (ppm) 
 Percent 
Reduction SEM  
Percent 
Reduction SEM  
Percent 
Reduction SEM 
Soyasaponin I 300  0.1 0.23  9.6a 1.45  46.3a 1.80 
 600  0.5 0.23  21.2b 0.95  52.3b 2.47 
 900  1.1 0.40  27.5c 0.78  60.1d 0.14 
Soyasaponin III 300  0.5 0.23  13.0a 0.41  48.5a 0.28 
 600  5.8a 0.15  21.2b 1.00  55.2c 0.15 
 900  5.8a 0.31  34.6d 1.57  65.3e 1.54 
Soyasapogenol B 50  0.3 0.12  67.2e 1.14  87.2f 0.75 
 100  14.7b 6.87  73.3f 1.90  88.4f 0.32 
 150  62.4c 0.99  87.9g 0.43  94.3g 0.29 
Data represents the percent reduction (%) compared with negative control and the standard error 
of the mean (SEM) (n = 3). Values in a column without common superscripts are significantly 
different (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. Morphological effects of treatment with 
and soyasapogenol B.  
 
(a) Untreated Caco-2 cell 
  
 
(b) Soyasaponin I treatment for 72 hours
(i) 300ppm   (ii) 600 ppm
 
(c) Soyasaponin III treatment for 72 hours
(i) 300ppm   (ii) 600 ppm
 
(d) Soyasapogenol B treatment for 72 hours
(i) 50 ppm   (ii) 100 ppm 
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Figure 7. Example of typical growth curves in a proliferation assay.  Figure taken from Oh et.al., 
2001 [66] 
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Table 4. Reduction of PKC by soyasaponins I, III, and sapogenol B 
Data represents the percent reduction (%) compared with control (cells+100ng/ml TPA) and the 
standard error of the mean (SEM) (n = 3). Values in a column without common superscripts are 
significantly different (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Conc. (ppm) 
 Percent Reduction 
(%) SEM 
Soyasaponin I 300  9.1a 1.82 
 600  16.4b 1.82 
 900  27.3c 1.82 
Soyasaponin III 300  18.2b 3.15 
 600  32.7c 1.82 
 900  40.0d 3.15 
Soyasapogenol B 50  56.4e 3.15 
 100  65.5f 1.82 
 150  70.9f 1.82 
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